Zim Laboratories

Zim Laboratories reported a Q4 FY26 total operating income of INR 105.3 crores, with EBITDA at INR 13.4 crores, resulting in a 12.7% margin. PAT for the quarter stood at INR 3.7 crores, reflecting sequential improvement. For the full fiscal year 2026, total operating income was INR 374.4 crores, broadly in line with FY25. Full-year EBITDA was INR 41.4 crores, and PAT was INR 5.8 crores. The company noted that profitability was impacted by elevated operating expenses and ongoing investments in regulatory compliance and quality infrastructure.

The company has substantially completed its CAPA implementation, addressing the majority of outstanding regulatory queries. A regulatory re-inspection by German and Portuguese authorities was conducted from May 4-7, 2026, at the Kalmeshwar manufacturing facility. Management expects a positive outcome from this inspection, with the formal draft report anticipated in the coming days. The previous EU GMP inspection in July 2025 was unsuccessful due to data integrity issues, which the company has since addressed through digitalization, automation, and strengthening its quality assurance team.

The MENA region, a strategically important market, experienced significant geopolitical disruption starting February 2026, leading to an estimated revenue impact of INR 20-25 crores for FY26. To mitigate such risks and ensure business continuity, Zim Laboratories has implemented proactive measures, including alternate certification and site transfer activities for select key products. An alternate CMO partner has been shortlisted for Star Product 1, with variations for the manufacturing site to be applied for soon, ensuring supply continuity with only marginal cost increases.

Revenue from New Innovative Products (NIP) and Oral Thin Films (OTF) stood at INR 25.4 crores in Q4 FY26, showing sequential improvement. The company aims for NIP and OTF products to constitute 50% of its total business in the future. All 17 products in the NIP/OTF pipeline are expected to be commercialized within the next 24 months. Commercialization of approved products in regulated markets, including the enzyme product, is anticipated to begin in Q4 FY27, with a target to scale the enzyme product to over INR 1500 crores by FY28.

Zim Laboratories has fully staffed its international business development function and made three senior leadership appointments, including a President of International Business and VPs for Quality Assurance, Human Resources, and Purchase, to strengthen capabilities. R&D spend was approximately 8.3% of revenues in FY26, a similar percentage is projected for FY27, reflecting a continued focus on developing new innovative products. Investments in digitalization and automation have been made to enhance data integrity and quality systems.

The company is optimistic about FY27, projecting 10-15% growth in its nutraceutical business and aiming for 'upper teens' EBITDA margins once regulated markets contribute significantly. INR 31.1 crores was allocated to BE studies and registrations for NIP and OTF platforms. Preferential issue proceeds of INR 35 crores are being deployed for a dedicated enzyme NIP suite, capacity expansion, and CAPA infrastructure. The company plans to keep borrowings constant for the current year, with finance costs also expected to remain stable, as it does not plan to increase borrowings further.